From 50,000 to 700,000 SKUs: Speed Parts Drives 20%+ Annual Growth with Maropost
SUNSHINE COAST, Australia, Sept. 2, 2025 /PRNewswire/ -- Speed Parts, one of…
HarperCollins India to publish Chetan Bhagat’s new romance
NEW DELHI, Sept. 2, 2025 /PRNewswire/ -- HarperCollins India is delighted to present…
SERES Posts Robust H1 2025 Results: Revenue Hits CNY 62.4 Billion, Net Profit Up 81% to CNY 2.94 Billion, R&D Investment Soars nearly 155%
CHONGQING, China, Sept. 3, 2025 /PRNewswire/ -- On August 29, SERES announced its…
Coventry and Alan Buerger Move to Dismiss Abacus Lawsuit
Motion underscores that Abacus's claims lack merit as Lapetus, its key life…
Coming Soon | GAC Will Officially Showcase Global Strategic Models at IAA Mobility 2025 in Munich
MUNICH, Sept. 3, 2025 /PRNewswire/ -- As one of the world's top…
TACC and CGT Unite to Drive Graphene Revolution
NEW DELHI, Sept. 2, 2025 /PRNewswire/ -- TACC Limited, a wholly owned…
ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones
ZEISS Medical Technology will showcase new ophthalmic innovations and market milestones at…
Herbalife India Honored with ‘Sustainable Supply Chain Award’ at BIGBOX India 2025
BENGALURU, India, Sept. 2, 2025 /PRNewswire/ -- Herbalife India, a premier health…
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
September 02, 2025 21:33 ET | Source: Mineralys Therapeutics, Inc. RADNOR, Pa.,…
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and…
